학술논문
A phase I/II study of 4 montly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients.
Document Type
Article
Author
Source
Subject
*BREAST cancer treatment
*DOSE-effect relationship in pharmacology
*GRANULOCYTE-colony stimulating factor
*DRUG therapy
*
*
*
Language
ISSN
0007-0920
Abstract
Determines the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cells and granulocyte-colony stimulating factor support as first-line therapy for hormone-refractory metastatic breast cancer patients. Management of hematological toxicity on an outpatient basis; Link between dose-limiting toxicity and chemotherapy-induced immuno-suppression.